Sweet’s syndrome is a neutrophilic dermatosis characterized by tender, erythematous, pseudovesicular plaques that can be associated with hematologic malignancy. We report a patient with recalcitrant Sweet’s syndrome...Sweet’s syndrome is a neutrophilic dermatosis characterized by tender, erythematous, pseudovesicular plaques that can be associated with hematologic malignancy. We report a patient with recalcitrant Sweet’s syndrome that preceded the development of myelodysplastic syndrome by 30 months. The delay between the onset of Sweet’s syndrome and the subsequent diagnosis of myelodysplasia highlights the need for thorough and repeated evaluation for underlying malignancy in patients with such a course. Although corticosteroids are the initial treatment of choice, this patient’s eruption was only partially responsive to high-dose prednisone andwas refractory tometronidazole, dapsone, and methotrexate. Treatmentwith thalidomide resulted in complete resolution of the cutaneous lesions within one month of therapy.展开更多
文摘目的:分析类风湿关节炎(Rheumatoid Arthritis,RA)疾病活动时血液学改变及反应疾病活动的炎性指标的变化,并探讨这些指标间的相互关系。方法:对住院治疗的120例RA疾病活动期患者进行回顾性研究,探讨血液学改变情况。结果:贫血发病率较高,为69.2%,主要为慢性病贫血(Anemia of chronic disease,ACD);中性粒细胞及单核细胞增高也较明显,中性粒细胞减少少见,淋巴细胞稍有减少,血小板增多多见。血小板与临床常用的几种炎症指标相关性分析显示有不同程度的相关性。结论:疾病活动期的RA患者血液学改变中贫血常见,主要为ACD,与代表铁储备的血清铁蛋白成负相关关系;血小板增多可以作为反应炎性反应活动的重要指标。
文摘Sweet’s syndrome is a neutrophilic dermatosis characterized by tender, erythematous, pseudovesicular plaques that can be associated with hematologic malignancy. We report a patient with recalcitrant Sweet’s syndrome that preceded the development of myelodysplastic syndrome by 30 months. The delay between the onset of Sweet’s syndrome and the subsequent diagnosis of myelodysplasia highlights the need for thorough and repeated evaluation for underlying malignancy in patients with such a course. Although corticosteroids are the initial treatment of choice, this patient’s eruption was only partially responsive to high-dose prednisone andwas refractory tometronidazole, dapsone, and methotrexate. Treatmentwith thalidomide resulted in complete resolution of the cutaneous lesions within one month of therapy.
